Sclerosis News and Research

RSS

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

For those who suffer from balance disorders and loss of mobility, promising results from a new stabilizing device may help to reestablish mobility, confidence and independence. This week, Motion Therapeutics premieres its BalanceWear™ Stabilizing Garments at the 24th Annual Meeting for the Consortium of Multiple Sclerosis Centers in San Antonio.

2 Jun 2010

State roundup: Ohio and Washington prepare high risk pool plans; Calif. lawmakers consider 20 bills; Virginia wrestles with Medicaid issues

A popular piece of the health-care overhaul bans insurance companies from denying individual coverage or charging high premiums to people with pre-existing medical conditions. But for adults younger than age 65, that provision doesn't kick in until 2014. In the meantime, the federal government wants states to create temporary high-risk pools through which people with cancer, multiple sclerosis and diabetes who have been uninsured for at least six months can buy affordable coverage.

2 Jun 2010

Firms chase opportunities in online medicine

General Electric Co. chief executive Jeffrey Immelt urged Japan, at a conference in Tokyo Monday, to use health information technology to improve home-based health care as a hedge against the strains of an aging population, The Wall Street Journal reports. Japan's over-65 population is growing, and could top 30 percent by 2030.

2 Jun 2010

New links discovered between Paul Klee's work and his 'scleroderma'

In 1933 Paul Klee's work was branded as 'Entartete Kunst' (Degenerate Art) by the National Socialists and he was dismissed from his professorial post at the Düsseldorf Academy of Fine Arts. This led him, together with his wife Lily, to return to his 'real home' of Bern. Here his avant-garde art was not understood and Klee found himself in unasked for isolation. In 1935 Klee started to suffer from a mysterious disease. The symptoms included changes to the skin and problems with the internal organs.

31 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

The Biotechnology Industry Organization (BIO) praised the Obama Administration for its new guidance, released today, that will lead to many small biotechnology companies receiving needed funding to support critical on-going research and development programs. The guidance document initiates the Therapeutic Discovery Project Program (TDPP), which was created by the Patient Protection and Affordable Care Act signed into law by President Obama on March 23.

25 May 2010

Sclerosis News and Research

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Multiple sclerosis risk sharing scheme: A costly failure

Amorfix Life Sciences signs licensing agreement with PREVENT

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

UCI study provides blueprint for enhanced treatment of inflammatory diseases

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

State roundup: Ohio and Washington prepare high risk pool plans; Calif. lawmakers consider 20 bills; Virginia wrestles with Medicaid issues

Firms chase opportunities in online medicine

New links discovered between Paul Klee's work and his 'scleroderma'

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News